OmniAb (OABI) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Verastem (VSTM) over the past year, gaining 166.3% versus a loss of 9.3%. Over five years, OABI leads with a -53.3% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($746.2 million vs $703.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OABI | VSTM |
|---|---|---|
| Share price | $4.84 | $8.24 |
| Market cap | $702.96M | $746.24M |
| 1-day change | +3.76% | +1.60% |
| YTD return | +151.89% | +5.05% |
| 1-year return | +166.29% | -9.28% |
| 5-year return | -53.26% | -75.51% |
| EPS (TTM) | $-0.36 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.43 | $10.82 |
| 52-week low | $1.30 | $3.43 |
| Distance from 52-week high | -10.96% | -23.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +72.29% | +82.04% |
| Average volume | 1.47M | 2.25M |
| Shares outstanding | 145.39M | 90.56M |
| Employees | 89 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed VSTM by 175.6 percentage points over the past year.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
OABI vs VSTM FAQ
Which is bigger, OmniAb or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $746.24M compared with $702.96M for OmniAb (OABI).
Which stock has performed better over the past year, OABI or VSTM?
OABI returned +166.29% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are OmniAb and Verastem in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for OmniAb and Biotechnology: Pharmaceutical Preparations for Verastem.